Thompson Siegel & Walmsley LLC bought a new stake in Solventum Co. (NYSE:SOLV - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 110,719 shares of the company's stock, valued at approximately $7,719,000. Thompson Siegel & Walmsley LLC owned 0.06% of Solventum as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also bought and sold shares of the company. Copeland Capital Management LLC acquired a new stake in shares of Solventum in the 3rd quarter valued at approximately $26,000. Mather Group LLC. bought a new stake in shares of Solventum during the third quarter worth $27,000. EverSource Wealth Advisors LLC bought a new stake in shares of Solventum during the first quarter worth $30,000. Hollencrest Capital Management bought a new position in shares of Solventum in the 2nd quarter valued at $25,000. Finally, Deseret Mutual Benefit Administrators acquired a new stake in shares of Solventum during the 2nd quarter valued at $25,000.
Solventum Stock Up 1.7 %
Shares of SOLV traded up $1.18 on Friday, reaching $70.81. The company's stock had a trading volume of 699,753 shares, compared to its average volume of 1,708,000. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The stock's 50 day simple moving average is $70.53 and its two-hundred day simple moving average is $62.35.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the stock. Wells Fargo & Company decreased their price target on shares of Solventum from $69.00 to $64.00 and set an "equal weight" rating for the company in a research report on Friday, August 9th. The Goldman Sachs Group increased their price objective on Solventum from $48.00 to $54.00 and gave the company a "sell" rating in a report on Monday, August 12th. Wolfe Research began coverage on Solventum in a report on Thursday, September 26th. They set a "peer perform" rating on the stock. Morgan Stanley increased their price target on Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Finally, Stifel Nicolaus started coverage on Solventum in a report on Tuesday, October 8th. They issued a "buy" rating and a $82.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Solventum has an average rating of "Hold" and a consensus target price of $68.00.
Check Out Our Latest Report on SOLV
Solventum Company Profile
(
Free Report)
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Recommended Stories
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
